Ustekinumab induction and maintenance therapy in refractory Crohn's disease. - Wikidata - wikimedia - TriplyDB

Ustekinumab induction and maintenance therapy in refractory Crohn's disease.

Ustekinumab induction and maintenance therapy in refractory Crohn's disease.

http://www.wikidata.org/entity/Q42514321

about

Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease Advances in the development of new biologics in inflammatory bowel disease Use of biologics and chemotherapy in patients with inflammatory bowel diseases and cancer Selective biologics for ulcerative colitis and Crohn's disease - clinical utility of vedolizumab Integrating Immunologic Signaling Networks: The JAK/STAT Pathway in Colitis and Colitis-Associated Cancer Genetics and Therapeutics in Pediatric Ulcerative Colitis: the Past, Present and Future Targeting Th17 Cells with Small Molecules and Small Interference RNA Ustekinumab for the treatment of Crohn's disease: can it find its niche?Hepatic manifestations of non-steroidal inflammatory bowel disease therapy Current stage in inflammatory bowel disease: What is next?Crohn's disease: a clinical update Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments Pharmacologic therapy for inflammatory bowel disease refractory to steroids Profile of ustekinumab and its potential in patients with moderate-to-severe Crohn's disease.Genetic update on inflammatory factors in ulcerative colitis: Review of the current literature Classical and recent advances in the treatment of inflammatory bowel diseases Pouring fuel on the fire: Th17 cells, the environment, and autoimmunity Review: The interleukin-23/interleukin-17 axis in spondyloarthritis pathogenesis: Th17 and beyond Review article: anti-adhesion therapies for inflammatory bowel disease Inflammatory pathways of importance for management of inflammatory bowel disease Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management Contribution of the IL-17/IL-23 axis to the pathogenesis of inflammatory bowel disease The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapy Gastrointestinal Disorders Associated with Common Variable Immune Deficiency (CVID) and Chronic Granulomatous Disease (CGD)Ustekinumab in Crohn's disease: evidence to date and place in therapy Dysregulation of Group 3 Innate Lymphoid Cells in the Pathogenesis of Inflammatory Bowel Disease Systematic review: treatment pattern and clinical effectiveness and safety of pharmaceutical therapies for Crohn's disease in Europe Translational Nano-Medicines: Targeted Therapeutic Delivery for Cancer and Inflammatory Diseases Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview.Psoriasis and comorbid diseases: Implications for management.Tyrosine Kinase 2-mediated Signal Transduction in T Lymphocytes Is Blocked by Pharmacological Stabilization of Its Pseudokinase Domain.Ustekinumab for the treatment of Crohn's disease.Role of interleukin 23 signaling in Clostridium difficile colitis Ustekinumab in chronic immune-mediated diseases: a review of long term safety and patient improvement Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases.Biologics in inflammatory bowel disease: what are the data?Neuroinflammation - using big data to inform clinical practice.Inflammatory bowel disease and celiac disease: overlaps and differences.Inflammatory Bowel Disease (IBD) pharmacotherapy and the risk of serious infection: a systematic review and network meta-analysis

P2860

Q24188040-4E0AEE02-3F56-4B1F-B2CE-4E716408C682 Q26745782-A9231592-AB77-4217-98F4-2DD43505FCD9 Q26750190-2559559B-0023-461E-AEB2-2C15FC749711 Q26750456-307D3127-71E7-4814-9A8A-624CF2A10D1B Q26764757-B8A2EEC2-284D-49DC-A3E2-2C817F448342 Q26765893-04D897A8-C400-4535-B596-F37F4409743E Q26770523-CE3AD88D-A2E7-4139-8AEB-C5458EDB432A Q26771890-B6ECC090-B5E1-4957-9B40-AD92AB2E2B34 Q26773684-10B88152-8A85-42AB-9D49-919505DF5C5A Q26777429-71924B9B-D1D6-4828-90A5-F635CE0212AF Q26777696-C6E36327-73FB-440D-A1D5-ABE2BF4C1775 Q26785537-0BDB1F60-9D9E-4C62-85F9-AAF68CCA97DB Q26796415-2B28004F-A987-40EC-B131-73AF49A094CE Q26825174-5CA9ED3A-56E1-4B65-929A-C334CF7F56AF Q26852514-5BFA694A-3B42-49DC-B06A-D83215534895 Q26861725-44E9F9C8-D25B-455E-896A-30FFC217A9EF Q26863295-973EB3AD-BE44-4773-8F9F-4CBE245BBE07 Q26991709-C6A3F7F4-F9A6-4E2E-BA17-6CB482743A04 Q26999705-D452789D-CDE8-4F7B-8B9C-8376C3158E3F Q27005445-D035D791-2AF4-425D-8A66-33C5F7806F38 Q27015831-1B6F130D-E69A-4DBA-B2ED-C1282AA8FCBC Q27027429-BFDDC3EF-B076-490D-8947-E2339B7F6455 Q27687800-2551AC6C-5CFA-4F8D-B71D-5E424F1486D8 Q28067631-7B49D64F-5A9E-496B-A184-7D3F62DA22AB Q28072810-5764CE6A-8669-4084-8D9C-55FC07A70844 Q28073787-8A7FCADC-78C5-4E35-88D3-E48037D26883 Q28075218-873312A4-B1FD-492D-ABA6-AFF164B83060 Q28080300-9EF812C0-BEF6-462F-B507-2FDA6F45C7CF Q28548580-69B4C75E-E881-4BC2-A83D-A784E370880B Q30235581-4353463D-6D19-4FBA-B03C-D2C0F72DF2CC Q30235888-45260A98-B408-49F6-9193-8525B82EAB42 Q30385239-9973CCE0-0CB3-44E2-A4D2-23D778105190 Q30390909-F699CD0D-D5B1-4532-A616-645CAF954E85 Q30410725-95BEB3DD-2202-458D-A9A8-9EB087190A91 Q30620977-8682E4BF-5113-4C78-86FF-2EC173B37157 Q30902172-550408A5-5725-4FAD-85B9-3899A7E86F08 Q31017419-06EEE0A6-3226-432D-8E35-8692BC6E9E69 Q31142833-709838B5-310C-49F7-AE3A-85D7F51FBA38 Q33564085-99DA81AE-ACAF-4655-8339-B48EC1694EF9 Q33564492-157D8E0B-DF20-4075-B80D-5B5C17F7048E

P2860

Ustekinumab induction and maintenance therapy in refractory Crohn's disease.

http://www.wikidata.org/entity/Q42514321

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Ustekinumab induction and maintenance therapy in refractory Crohn's disease.

@en

Ustekinumab induction and maintenance therapy in refractory Crohn's disease.

@nl

type

label

Ustekinumab induction and maintenance therapy in refractory Crohn's disease.

@en

Ustekinumab induction and maintenance therapy in refractory Crohn's disease.

@nl

prefLabel

Ustekinumab induction and maintenance therapy in refractory Crohn's disease.

@en

Ustekinumab induction and maintenance therapy in refractory Crohn's disease.

@nl

P1433

Q42514321-A470D24D-4AF0-435F-8F0F-DFF71DB39428

P1476

Q42514321-A73DE5D7-1179-4691-9ABF-3AD93C515B74

P2093

Q42514321-034956C4-621E-4FF1-AD90-A1B602949434

Q42514321-196D87DC-6CBD-4152-89DA-9AD44FC331FB

Q42514321-43FF32AA-25C7-4224-B493-B3A360DBC358

Q42514321-46CD24BC-57A3-4B62-B170-9FED13E8955B

Q42514321-4D1BB1F2-5C2B-414A-8598-732E1DB74DDE

Q42514321-53656B89-6241-4D59-A476-AC268B5543B5

Q42514321-5C67DFAD-ADE6-47A3-9DF2-FA7FF44E926D

Q42514321-76F9C13A-AB9B-4A83-A698-85323F521E39

Q42514321-8A91994F-96F4-41A6-9513-5B430C1B7E7F

Q42514321-A0C3CA0C-B9F8-4758-8B3D-B528A20C470A

P304

Q42514321-CE59E48C-FC2E-4F98-BBCA-CD64339ED940

P31

Q42514321-6C2F2A70-1DB7-4DF3-BDB8-EBD8AEA299BA

P356

Q42514321-A6C99125-B03E-4053-A226-C728331046D4

P407

Q42514321-647C5394-BFF6-4E8F-8C54-3C569098FDA3

P433

Q42514321-95C957D8-A933-4BEA-B059-E58D2672D0F8

P478

Q42514321-F7E661A6-6050-4FAC-9C96-50352785C17F

P50

Q42514321-9F2E9132-6789-4BE3-9F1C-CA3E4C0D709C

Q42514321-D278517C-150D-4F7C-89F6-78A9607C025A

Q42514321-E28BC514-687B-461C-9069-BA4A924A3D38

P577

Q42514321-F9AD2DD3-0C20-436B-B1B2-D2297DC82353

P5875

Q42514321-945EC1E8-933E-4616-AA02-0E1A62756A71

P698

Q42514321-20D68FD8-3071-4444-B9E4-DFF3DF8E048E

P356

P1433

The New England Journal of Medicine

P1476

Ustekinumab induction and maintenance therapy in refractory Crohn's disease.

@en

P2093

Bruce E Sands

http://www.w3.org/2001/XMLSchema#string

CERTIFI Study Group

http://www.w3.org/2001/XMLSchema#string

Christopher Gasink

http://www.w3.org/2001/XMLSchema#string

Cynthia Guzzo

http://www.w3.org/2001/XMLSchema#string

Gordon Greenberg

http://www.w3.org/2001/XMLSchema#string

Jewel Johanns

http://www.w3.org/2001/XMLSchema#string

Long-Long Gao

http://www.w3.org/2001/XMLSchema#string

Marion A Blank

http://www.w3.org/2001/XMLSchema#string

Remo Panaccione

http://www.w3.org/2001/XMLSchema#string

Simon Lichtiger

http://www.w3.org/2001/XMLSchema#string

P304

1519-1528

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1203572

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

367

http://www.w3.org/2001/XMLSchema#string

P50

William Jeffery Sandborn

Brian G. Feagan

P577

2012-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

232279582

http://www.w3.org/2001/XMLSchema#string

P698

23075178

http://www.w3.org/2001/XMLSchema#string